Latest news with #DiabeticMacularEdema
Zawya
15-05-2025
- Health
- Zawya
Saudi Arabia hosts landmark Ophthalmology Meeting to advance (DME) and (RVO) Treatment
Under the title 'Holistic pro-Inflammatory Target for Sight (HITS)' the Ophthalmology Pivotal Meeting kicked off in Saudi Arabia on April 25, 2025, under the auspices of AbbVie, the global biopharmaceutical research and development company. This is a significant move to elevate the standard of care for various eye conditions like Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). More than 100 national and international ophthalmologists participated in the meeting, which included scientific lectures and in-depth workshops to leverage applied medical specialties in ophthalmology and optics, exchange knowledge and expertise, and help change perspectives on the best ways to improve patient outcomes. It also discussed treatment and management methods of these prevalent diseases. In his lecture, Dr. Mattias Iglicki, Consultant Ophthalmologist, Vitreoretinal Surgeon and Researcher from University of Buenos Aires, Argentina, praised the convening of this meeting, which is a good opportunity to discuss the latest advancements and clinical trials in the presence of this elite group of international retinal specialists, along with local experts. He explained that diabetic macular edema, which is often the result of high blood sugar levels in diabetics, accompanied with leaky blood vessels leading to swelling in the retina. On the other hand, retinal vein occlusion occurs when the retinal veins are blocked, causing fluid buildup and impaired vision. Both conditions are serious and require proactive management to prevent the disease from worsening. Dr. Iglicki emphasized that organizing such medical summits and conferences serves as a platform for sharing and disseminating the cutting-edge research and developments in treating eye diseases, especially DME and RVO, which are diseases whose rates are increasing with the increasing incidence of diabetes. This enables the attending ophthalmologists to implement these updates in their practices, which in turn advances treatment methods in the Kingdom of Saudi Arabia in accordance with the latest international recommendations and technologies, thus improving the lives of patients and alleviating their daily suffering. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, pointed out that Saudi Arabia's hosting of such medical meetings and seminars reflects the Kingdom's interest in promoting medical education and exchanging scientific expertise between international and local physicians to highlight the most important scientific and medical developments and provide distinguished medical care. By organizing this congress, AbbVie underscores its commitment to enhancing patient outcomes through educational initiatives and collaboration among eye care professionals. Sharing knowledge and expertise at such events is crucial to our ongoing efforts to refine treatment strategies, improve patients' quality of life, and help make a real difference in their lives. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
Zawya
15-05-2025
- Health
- Zawya
Saudi Arabia hosts landmark ophthalmology meeting to advance DME and RVO treatment
Under the title 'Holistic pro-Inflammatory Target for Sight (HITS)' the Ophthalmology Pivotal Meeting kicked off in Saudi Arabia on April 25, 2025, under the auspices of AbbVie, the global biopharmaceutical research and development company. This is a significant move to elevate the standard of care for various eye conditions like Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). More than 100 national and international ophthalmologists participated in the meeting, which included scientific lectures and in-depth workshops to leverage applied medical specialties in ophthalmology and optics, exchange knowledge and expertise, and help change perspectives on the best ways to improve patient outcomes. It also discussed treatment and management methods of these prevalent diseases. In his lecture, Dr. Mattias Iglicki, Consultant Ophthalmologist, Vitreoretinal Surgeon and Researcher from University of Buenos Aires, Argentina, praised the convening of this meeting, which is a good opportunity to discuss the latest advancements and clinical trials in the presence of this elite group of international retinal specialists, along with local experts. He explained that diabetic macular edema, which is often the result of high blood sugar levels in diabetics, accompanied with leaky blood vessels leading to swelling in the retina. On the other hand, retinal vein occlusion occurs when the retinal veins are blocked, causing fluid buildup and impaired vision. Both conditions are serious and require proactive management to prevent the disease from worsening. Dr. Iglicki emphasized that organizing such medical summits and conferences serves as a platform for sharing and disseminating the cutting-edge research and developments in treating eye diseases, especially DME and RVO, which are diseases whose rates are increasing with the increasing incidence of diabetes. This enables the attending ophthalmologists to implement these updates in their practices, which in turn advances treatment methods in the Kingdom of Saudi Arabia in accordance with the latest international recommendations and technologies, thus improving the lives of patients and alleviating their daily suffering. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, pointed out that Saudi Arabia's hosting of such medical meetings and seminars reflects the Kingdom's interest in promoting medical education and exchanging scientific expertise between international and local physicians to highlight the most important scientific and medical developments and provide distinguished medical care. By organizing this congress, AbbVie underscores its commitment to enhancing patient outcomes through educational initiatives and collaboration among eye care professionals. Sharing knowledge and expertise at such events is crucial to our ongoing efforts to refine treatment strategies, improve patients' quality of life, and help make a real difference in their lives. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Yahoo
14-05-2025
- Business
- Yahoo
Angelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases
Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio's lead candidate, THN391, for the treatment of Alzheimer's Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a fibrin/VEGF bispecific Investment demonstrates Angelini's continued strategic focus in neurodegenerative disease Rome, Italy, 14 May 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, today announces its participation in a $39 million extension of the Series A financing round for Therini Bio, a US-based clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction. Angelini Ventures joins a syndicate of top-tier international healthcare investors in Therini Bio, including new investor Apollo Health Ventures and existing investors SV Health Investors' Biotech Fund and the Dementia Discovery Fund, Dolby Family Ventures, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund and Sanofi Ventures. This latest close brings the total raised by Therini Bio, in its Series A round – first announced in April 2023 – to $75 million. This investment builds on Angelini Ventures' expertise in neurodegeneration, following its recent investments in Neumirna Therapeutics and Arclight Therapeutics. The funds raised by Therini Bio through its extended Series A financing will enable the company to advance Phase 1b studies evaluating its lead candidate, THN391, a potential first-in-class monoclonal antibody designed to selectively block fibrin-mediated neuroinflammation, for the treatment of Alzheimer's Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a fibrin/VEGF bispecific. Thomas Thestrup, Ph.D., Senior Principal at Angelini Ventures and deal lead, said 'We are proud to support Therini Bio's mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. As an active investor in companies developing next-generation treatments for neurodegenerative and other CNS disorders, we are excited about Therini Bio's first-in-class selective antibody therapy targeting fibrin-mediated inflammation, offering a groundbreaking path to transform the treatment of diseases such as Alzheimer's and Diabetic Macular Edema.' Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will join Therini Bio's Board of Directors as a Board Observer. Tara Nickerson, Ph.D., Chief Executive Officer of Therini Bio, said 'We are deeply grateful to partner with such a distinguished investor group, both new and old. Their support enables us to significantly advance our shared vision of delivering patients a rational, innovative approach to potentially treat their debilitating conditions, including AD and DME. We look forward to advancing the Phase 1b trials to demonstrate the benefit of this novel mechanism in patients.' Notes to EditorsAbout Angelini Ventures Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. Angelini Ventures will invest €300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies. To date, Angelini Ventures has invested around €100 million into 18 companies covering a range of therapeutic areas and modalities. Angelini Ventures' BioTech portfolio includes Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The Company's Digital Health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis. About Angelini Industries Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over two billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it About Therini Bio Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. Therini is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer's disease and Diabetic Macular Edema, where destructive neuroinflammation plays a central role in the disease process. Therini Bio's top-tier syndicate of life sciences investors includes the Alzheimer's Drug Discovery Foundation, Angelini Ventures, Apollo Health Ventures, SV Health Investors' Biotech Fund and Dementia Discovery Fund, Dolby Family Ventures, Dreavent Biotech Investments, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and Sanofi Ventures. For more information, visit ContactsAngelini VenturesMartina Palmese, Communications Media contacts for Italy - SEC Newgate ItaliaDaniele Pinosa, Tel. +39 3357233872Fausta Tagliarini; Tel. +39 3476474513Daniele Murgia; Tel. +39 3384330031 Media contacts outside Italy - MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Mark Swallowangeliniventures@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-02-2025
- Business
- Yahoo
BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...
ORLADEYO Revenue Growth: 34% year-over-year increase for 2024. Total Revenue for Q4 2024: $131.5 million. ORLADEYO Revenue for Q4 2024: $124.2 million. Total Revenue for Full Year 2024: $450.7 million. ORLADEYO Revenue for Full Year 2024: $437.7 million. Non-GAAP Operating Profit for 2024: Over $60 million. Operating Expenses for Q4 2024: Approximately $115 million (excluding non-cash stock compensation). Operating Expenses for Full Year 2024: $388 million (excluding non-cash stock compensation). Cash at Year-End 2024: Approximately $343 million. Net Cash Utilization for Q4 2024: $8.4 million. 2025 ORLADEYO Revenue Guidance: Raised to $535 million to $550 million. 2025 Total Revenue Guidance: Adjusted to $560 million to $575 million. Warning! GuruFocus has detected 7 Warning Signs with BCRX. Release Date: February 24, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a 34% year-over-year growth in ORLADEYO revenue for 2024, indicating strong market performance. The company achieved a non-GAAP operating profit of over $60 million, which was three times larger than planned, showcasing effective financial management. BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is advancing its pipeline with promising clinical trials for BCX17725 for Netherton Syndrome and Avoralstat for Diabetic Macular Edema. The company is on track to file an NDA for ORLADEYO for pediatric use, expanding its market potential to children aged 2 to 11. BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) raised its ORLADEYO revenue guidance for 2025 to $535 million to $550 million, reflecting strong demand and favorable impacts from the Inflation Reduction Act for Medicare patients. The company faces uncertainty around future government funding for RAPIVAB, which could impact revenue streams. There is a potential headwind from foreign exchange rates, particularly affecting revenue from the European Union. BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) anticipates flat to slightly down revenue in Q1 2025 due to the reauthorization season and gross-to-net impacts. The company acknowledges that the Netherton Syndrome market is underdiagnosed, which could pose challenges in patient identification and market penetration. Despite the positive outlook, the company remains cautious about the variability in ex-US demand and the impact of distributor shipment timing on quarterly results. Q: Can you provide more details on the expected timeline for Netherton Syndrome data and what constitutes positive data? A: Helen Thackray, Chief Research & Development Officer: We expect to have data this year. For Netherton Syndrome, we only need data from a small number of patients to confirm the mechanism. We're looking for the drug's effect on KLK5 activity in the skin, leading to healing. If successful, we could move quickly into pivotal studies, potentially with a single pivotal trial supported by this year's data. Q: What is the current status of ORLADEYO's paid patient proportion, especially within Medicare? A: Charles Gayer, Chief Commercial Officer: We ended last year with 73.5% paid across our patient base. For Medicare, it was lower, around 55-56%. We expect this to improve significantly due to the Inflation Reduction Act, potentially reaching 80% by the end of the quarter. Q: How does the pediatric formulation of ORLADEYO compare in terms of tolerability and regulatory expectations? A: Helen Thackray, Chief Research & Development Officer: The pediatric oral granules show good tolerability and similar efficacy to adults. Regulatory approval will follow a pediatric extrapolation approach, matching safety and exposure to extend labeling from adults to children. We are on track with the FDA and EMA for this process. Q: What are the expectations for ORLADEYO's international demand in 2025, considering the Q4 uptick? A: Charles Gayer, Chief Commercial Officer: We see growing confidence in ORLADEYO internationally, with transformative confidence in markets like the UK and early confidence in Italy. Despite FX headwinds, we expect continued growth, although the percentage of ex-US revenue might be slightly deflated due to strong US growth. Q: How is BioCryst addressing the underdiagnosis of Netherton Syndrome? A: Charles Gayer, Chief Commercial Officer: We are expanding our efforts to identify patients, focusing on distinctive features like bamboo hair. We plan to educate the market and engage with the patient community to improve diagnosis and awareness as we move into clinical trials. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
